Show simple item record

dc.contributor.authorLópez Cano, Carolina
dc.contributor.authorCiudin, Andreea
dc.contributor.authorSánchez Peña, Enric
dc.contributor.authorTinahones, Francisco José
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorDalmases, Mireia
dc.contributor.authorGarcía Ramírez, Marta
dc.contributor.authorSoto, Alfonso
dc.contributor.authorMichela Gaeta, Anna
dc.contributor.authorPellitero, Silvia
dc.contributor.authorMartí, Raquel
dc.contributor.authorHernández, Cristina
dc.contributor.authorSimó, Rafael
dc.contributor.authorLecube Torelló, Albert
dc.date.accessioned2022-03-03T08:59:31Z
dc.date.available2022-03-03T08:59:31Z
dc.date.issued2022
dc.identifier.issn0012-1797
dc.identifier.issn1939-327X
dc.identifier.urihttp://hdl.handle.net/10459.1/73145
dc.description.abstractTo evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted. Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily). This short duration was intentional to minimize weight loss as a potential confounding factor. Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity. Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009). No differences in the other pulmonary variables were observed. Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038). The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = −0.313, P = 0.036). Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC. In conclusion, liraglutide increased FVC in patients with type 2 diabetes. This effect was associated with a significant decrease of circulating SP-D, thus pointing to a beneficial effect in the alveolar-capillary function.ca_ES
dc.description.sponsorshipCIBERDEM and CIBEROBN are initiatives of Instituto de Salud Carlos III (PI 15/00260 and PI 18/00964). The drugs under study were supplied by Novo Nordisk at the request of the sponsor of the study expressly for the clinical trial, with Novo Nordisk taking responsibility for the manufacture, packaging, and labeling.ca_ES
dc.language.isoengca_ES
dc.publisherAmerican Diabetes Associationca_ES
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.2337/db21-0688ca_ES
dc.relation.ispartofDiabetes 2022, vol. 71, núm. 2, p. 315–320ca_ES
dc.rights(c) American Diabetes Association, 2021ca_ES
dc.titleLiraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Studyca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec031771
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.2337/db21-0688


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record